Oxygen is a neonatal health hazard that should be avoided in clinical practice. In this review, an international team of neonatologists and nurses assessed oxygen saturation (SpO 2 ) targeting in preterm infants and evaluated the potential weaknesses of randomised clinical trials.
INTRODUCTION
The toxic nature of excess oxygen has been causing concern for more than 200 years. Despite these concerns, oxygen is the most commonly used drug in neonatal intensive care units (NICUs) around the world. We sometimes fail in our laudable attempts to prevent and avoid hypoxia by unnecessarily exposing newborn infants worldwide to levels of oxygen that are too high and to hyperoxic states. Hyperoxia for which it is prescribed. It invariably affects other functions and organ systems' (1, 2) . In 1955, he also stated that 'Pulmonary physiologists understand pulmonary physiology reasonably well. Many doctors and medical students do not' (3) (4) (5) . It is disappointing that a similar statement could be applied today to neonatal oxygenation physiology. As early as 1939, Comroe demonstrated the deleterious effects of oxygen, when he showed that oxygen provided during asphyxia-induced aortic chemoreceptor discharge caused an abrupt decrease in arterial blood pressure (6) . Furthermore, in the early 1950s, he warned us about the adverse effects of oxygen in the lung, with uneven alveolar ventilation during a single breath of 100% oxygen, and on respiratory control and mental status, with mental changes during oxygen therapy (3) (4) (5) .
Since then, we must constantly remind ourselves that too much of a good thing can be poisonous. Hyperoxaemia can be pernicious, and there is no clinical or pathophysiological condition known to cause it. Therefore, each time undue oxidant stress occurs, it is likely to be caused by excess or unnecessary oxygen administered by healthcare providers or by reperfusion after hypoxaemia.
In 2007, we stated that inappropriate oxygen use is a neonatal health hazard associated with many morbidities and that neonatal exposure to pure oxygen, even briefly, or to pulse oximetry of more than 95% when breathing supplemental oxygen must be avoided as much as possible (1) . The highly positive editorial that accompanied our paper (7) said that our manuscript 'should be obligatory reading for everyone working with newborn intensive care' and added that 'we should all take a deep breath and consider Sola et al.'s proposal to stop inducing hyperoxia in any newborn infant as long as we do not know the shortand long-term consequences of such a practice' (7) .
Unfortunately, despite many older and recent studies, there is no evidence to demonstrate the perfect oxygen saturation (SpO 2 ) target for daily neonatal practice, and SpO 2 targeting in preterm infants remains a very controversial worldwide topic. However, findings of recent randomised clinical trials (RCTs) (8) (9) (10) (11) and published commentaries and meta-analyses (12, 13) have added significant insight and allow for discernment.
While investigators are looking for further improvements, neonatal oxygenation is not well understood by many caregivers, and oxygen is often given at fickle, capricious or whimsical doses, with SpO 2 interpreted erroneously in many newborns. Of course, trying to avoid hyperoxaemia does not equate to permitting hypoxaemia. Through the years, it has become evident that no neonatal bedside care provider leaves an infant unattended if hypoxia is suspected or confirmed. However, the same does not always apply when hyperoxaemia may be present, despite advancing knowledge of cerebral oxygenation, extraction and auto regulation in very preterm infants. It is becoming possible to assess the presence of excess oxygen in the brain, but this is not yet widely used by clinicians. We have been concerned, recently, to learn that high regional cerebral saturation has been potentially associated with peri-intraventricular haemorrhage and with poor outcome at 2 years of age (14) .
Regrettably, blindness due to retinopathy of prematurity (ROP) is a serious and epidemic health problem in Latin America and many other regions of the world. At the moment, many neonatal clinical care providers in North America, Central and South America and Europe are somewhat confused about which SpO 2 target should be used. It is likely that changed clinical protocols are, once again, exposing many babies to unnecessary and potentially detrimental hyperoxia. Our current level knowledge connotes that we do not know the ideal SpO 2 target range and cannot formulate best practice in this area. Instead, it may be prudent to avoid and eradicate possible bad practices that could prove detrimental to newborn infants. For example, recommending a low or narrow SpO 2 target range is not realistic in clinical practice and could have ill effects for preterm infants worldwide.
The aim of this review is to provide an additional view, supported by objective data, on this complex and unresolved issue. We present salient points from recent RCT's and highlight their relevant differences and the likely reasons for those differences. This enables us to summarise and clarify points on the value on SpO 2 targeting for clinical practice. Finally, we also include some clinical concepts regarding SpO 2 monitoring and comments on why some RCTs may be flawed, based on the views presented by Ioannidis et al. (15) . Our objective is that newborn infants should not be exposed to hypoxia at all and that potentially damaging hyperoxia should also be avoided as much as possible during daily neonatal clinical practice.
EVIDENCE FROM THE SUPPORT, BOOST II AND COT
This section looks at five major randomised controlled trials that were carried out as masked, prospective evaluations comparing two SpO 2 target ranges -85-89% vs 91-95% -in a large number of infants of <28 weeks of gestation. They are the US SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network (SUPPORT), the Benefits of Oxygen Saturation Targeting (BOOST II) trial, which covered the UK, Australia and New Zealand and the Canadian Oxygen Trial (COT) (8) (9) (10) (11) . There were five RCTs, but the neonatal outcomes of the three BOOST II trials were pooled and reported as a single study. We understand that this was a deviation from the original plan and was prompted by the interim subgroup analysis. This review refers to the findings of the studies as they have been published to date (8) (9) (10) (11) . All these RCTs compared the results between infants randomly assigned to the lower SpO 2 target (85-89%) and the higher intention to treat (91-95%) target. The targets studied were narrow, and no other SpO 2 ranges or targets were compared.
In all the trials, the oximeters were modified to display and store SpO 2 levels that were either 3% higher or lower than the true values. True SpO 2 values were displayed if the measured SpO 2 values were <84% or more than 96%. During two trials (10, 11) , the algorithms of the SpO 2 monitors were changed, both algorithms functioning within specifications approved by the US Food and Drugs Administration (FDA). The primary outcome variables were similar among the trials and comprised the composite outcome of the death or disability rate at 18 or 24 months. In the SUPPORT trial, the primary outcome of the shortterm part of the trial was a composite of severe ROP, death before discharge from the hospital or both. The primary composite outcome for the longer-term analysis was death before assessment at 18-22 months or neurodevelopmental impairment at 18-22 months of corrected age.
SUMMARY OF THE KEY FINDINGS REPORTED BY THE RCTS
The two groups were separated and analysed by randomised assignment and intention to treat. However, there were varying degrees of SpO 2 overlap between the two groups, with variable percentages of time when the infants assigned to the SpO 2 target ranges of 85-89% were in the 91-95% range and vice versa. The overlap was not the same for all studies, but in all the studies, the low-targetrange group had median SpO 2 readings at, or beyond, the upper limit of this range. This meant that the separation between the SpO 2 readings was around 3-4%, instead of 6% as intended. Additionally, the amount of time spent with SpO 2 below 85% in the lower-target group and with SpO 2 above 95% in the higher-target group was not the same when we compared the findings published by the RCTs. This is not at all unexpected. It has been well described previously that, in clinical practice, achieved versus intended SpO 2 is very variable and depends on several factors.
In the SUPPORT study, an SpO 2 target of 85-89% was associated with increased mortality at the time of discharge, compared with the higher target of 91-95% (19.9% vs 16.2%; p = 0.045). In the BOOST trial, recruitment was stopped early when an interim analysis showed an increased death rate at 36 weeks in the group with lower oxygen saturation. The authors analysed pooled data and reported hospital discharge outcomes (11) and found that mortality was higher in the lower-target group (23.1% vs 15.9%, relative risk: 1.45 95% confidence interval 1.15-1.84; p = 0.002). It is unclear why the death rate was higher in the lower-target group and the best estimate of the effect of SpO 2 on mortality from these trials is unknown. Other interventions that influence oxygen targeting may also influence mortality (11) . The COT (10) reported findings at 18 months, after the ascertainment of the primary outcome variable, and reported no difference in mortality between the lower and higher targets. No study has shown that targeting any other lower range apart from 85 to 89%, for example 85% to 93% or 94%, has been associated with increased mortality. On the other hand, several descriptive clinical studies showed decreased rates of ROP, together with decreased exposure to oxygen, ventilator days and incidence of bronchopulmonary dysplasia, without any association with mortality, when SpO 2 targets were 85-94% or similar (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) .
In the SUPPORT and BOOST II trials, SpO 2 targets of 91-95% were associated with a higher incidence of severe ROP compared with SpO 2 levels of 85-89%, at the same time points mentioned above. Therefore, if clinicians could only chose one of the ranges investigated by the published RCTs, targeting an SpO 2 range of 91-95% is clearly safer than 85-89%. On the other hand, the COT did not find such a difference at 18 months and does not support this suggestion. Importantly, none of the RCTs, and no other published studies, have shown that an intended SpO 2 of 91-95% is the safest range for clinical practice and that using any other target is a bad choice. Not using SpO 2 of 85-89% does not necessarily mean that infants have to be treated with a desired SpO 2 target of 91-95%.
Additionally, there were no differences in neurodevelopment, intracranial haemorrhage, patent ductus arteriosus or bronchopulmonary dysplasia between the two target groups. Necrotising enterocolitis was more frequent with SpO 2 85-89% in BOOST II, but not in the COT or SUPPORT trials. Finally, when the SUPPORT investigators reported longer-term results from their prespecified hypotheses (9), they found no significant differences in the composite outcome of death or neurodevelopmental impairment among extremely premature infants randomly assigned to a lower-or higher-target range of oxygen saturation at 18-22 months. However, as reported at 36 weeks (8), mortality was modestly increased in the lower-target group (85-89%) and severe ROP was greatly increased in the higher-target group (91-95%). COT (10), as mentioned, found no differences in the composite outcome of death or disability at 18 months. The primary outcome variable has yet to be reported by BOOST II.
COMMENTS ON THE DIFFERENT FINDINGS IN THE RCTS
The differences between the findings of these RCTs may be due to many factors, including important differences in design, implementation and data handling. These issues may also affect the ability to perform and interpret metaanalyses, as briefly mentioned later (15, (26) (27) (28) .
The COT did not perform an interim analysis and ascertained the primary outcome variable before analysing any of the trial data. Some of the findings reported by the BOOST II trial were after interim analysis, repeated testing and with data-driven investigator-initiated questions. The possible impact of performing interim analysis is addressed towards the end of this paper. Other differences in the reported data include that the mortality rates were lower in the COT (15.9%) than the SUPPORT (20.1%) and BOOST II trials (23.1%). These dissimilar rates may also partly explain the differences in mortality. Furthermore, a smaller proportion of the COT infants had median SpO 2 <85% and >95%, and the distributions of SpO 2 in the two treatment groups overlapped less. Additionally, there were some differences in clinical protocols. For example, alarm settings varied, and the lower saturation thresholds that would trigger an alarm were not prescribed in the UK protocol, which formed part of BOOST II. These, and other differences, may explain why there was no excess mortality in the low-target group in the COT or excess ROP in the high-target group.
SPO 2 MONITORING
The following observations are based on extensive peer reviewed publications, on what is summarised above and on previously acquired knowledge (17, 19, (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) . There have been more than 200 publications on the subject since the late 1990s, and as space is limited in the journal, a fuller reference list is available from the corresponding author.
All SpO 2 monitors have an inherent bias when they function according to their specification. However, the failure to provide accurate readings varies between monitors. Also, SpO 2 monitors offer different accuracy levels and precision and differ in the time they take to respond and in the number of false alarms, missed events and detection of true events.
Specificity and sensitivity rates of false-positives and false-negatives and therefore receiver operating curves are also different between different SpO 2 monitors. Finally, they also differ in their ability to provide accurate measurements through motion and low perfusion. The SpO 2 monitor chosen by the investigators for the important RCTs covered by this review (8-11) features signal extraction technology (SET) and is manufactured by Masimo (Masimo Corporation, Irvine, CA, USA). More than 100 publications have stated that it functions more accurately and precisely than any other SpO 2 monitor, and it is approved by the FDA to measure through motion and low perfusion.
Due to bias and in line with the Gaussian curve of normal distribution, the SpO 2 read-out is within AE one standard deviation (SD) of the true arterial saturation 68% of the time. For example, when the SpO 2 read-out is 90%, and the equipment bias is 1%, 68% of the time the true arterial saturation will be 89%, 90% or 91%. If, on the other hand, the monitor has a bias of 3%, then when the monitor reads an SpO 2 of 90%, the arterial saturation will be between 87% and 93% for 68% of the time. In two individuals with exactly the same SpO 2 read-out, the true arterial SaO 2 could therefore be 1-3% different from each other for 32% of the time. Therefore, a difference of 1-2% in the reading of the SpO 2 monitor may be inconsequential. This lends support to using wider target ranges and suggests that it does not make much sense to spend much time arguing if an SpO 2 of 89% is significantly worse than an SpO 2 of 91% for an individual baby.
The algorithms of SpO 2 study monitors were changed during the randomised studies, but both algorithms function within specifications approved by FDA and do not affect care when addressing the needs of an individual baby. The COT, which did not performed any interim analysis, found no significant differences in the SpO 2 readings when it compared the software of the two algorithms, with differences of 0.3% and 0.5% in the low-and high-target groups, respectively. In addition, in the COT, replacing the oximeter software was not associated with improved targeting of the SpO 2 values in either group.
POINTS WITH POTENTIAL VALUE FOR CLINICAL CARE Alarms
There are many alarms in the NICU over the course of a day, and this has been identified as a safety issue. Many of the alarms are not related to true clinical problems and are considered false alarms. There are also alarms that are true alarms but do not require any intervention. Obviously, the narrower the SpO 2 targeting range and alarm limits chosen, the greater the number of alarms. In addition, the high alarm is violated more frequently than the low alarm. For example, a study of alarm limits for pulse oximetry in very preterm infants at the Royal Women's Hospital in Melbourne, using an SpO 2 target of 85-94%, found that the lower alarm limit was set correctly 91% of time, but the upper limit only was set correctly 23% of the time. It is noteworthy that for 24% of the time the upper alarm limit was set at 100% (45) . Due to legitimate concerns about hypoxia, many registered nurses will change the upper-limit alarm more frequently, but not the lower one, if it becomes difficult to maintain the infant within a narrow range. We also know that there is less response to high alarms in clinical care. All this is associated with an increased tolerance of SpO 2 ≥95%, which would increase the percentage of time with hyperoxia; as a study of 1000 samples found that at an SpO 2 > 94%, 60% of the samples had a partial pressure of oxygen in arterial blood (PaO 2 ) of more than 80 mmHg (19) . The alarm limits should be set no more than 1% or 2% above or below the chosen target range and should always be on. The lower alarm should always be ≥85%. We consider that in infants breathing supplemental oxygen, the high alarm should be set at 95% to avoid PaO 2 of more than 80 mmHg, and the high alarm value chosen should always be operative while the infant is breathing a fraction of inspired oxygen (FiO 2 ) of more than 0.21. It cannot be overemphasised that it is clinically mandatory to choose and set alarms appropriately and to ensure the alarm system is always operative. Of course, when an infant previously receiving oxygen reaches room air, then the upper alarm limit needs to be deactivated.
One issue that may affect clinical practice in the NICU is that some monitors have a desaturation alarm limit as well as a low-limit alarm, and each can be set independently with different SpO 2 values. Some of these monitors have a soft volume and yellow light for the low-limit alarm. If the SpO 2 falls below the set desaturation limit, the alarm sound changes markedly, becoming strident, and the light turns red, signalling that there is a potentially serious situation. Interestingly, the high alarm only has a softer sound and a yellow light, with no option for a more strident alarm or red light.
Averaging time and sensitivity
Pulse oximeter saturation values are usually obtained by averaging preceding measurements. Some SpO 2 monitors allow clinicians to modify the averaging time and sensitivity or both at the same time. This has an impact on the monitor's response and therefore on what the clinicians observe in the digital display in the same infant at the same time. With monitors that provide this function, the number of desaturations, and therefore alarms, is greater with the short, 2-sec averaging time. However, this does not reach significance when only desaturations of clinically significant duration are considered. On the other hand, a long averaging time of 16 sec reduces the detection of brief periodic desaturation events and of those of greater severity. It may also interpret a cluster of shorter events as a single, prolonged episode and, as a result, potentially overestimate the frequency of long events (40) . Another study that recorded desaturations of SpO 2 <80% found that there were 339 when using an average time of 16 sec and 1958 when an average time of 3 sec was used. There was a significantly lower-pulse oximeter saturation nadir with the shorter averaging time, while the maximum duration was significantly longer with the 16 sec averaging time (44) . These findings demonstrate that there are pros and cons with each of the settings, depending on the infant's condition. Careful attention should therefore be paid to averaging time and sensitivity in the monitors used for clinical care. The performances of monitors manufactured by different companies vary, and some have default settings that cannot be modified, and it is our responsibility to understand the monitors we use in clinical care. In the delivery room, when changes may occur rapidly during resuscitation, maximum sensitivity and an average time of 2 sec is recommended. However, this is not the case for a critically ill infant in the NICU, as these settings could alarm the clinician by alerting him or her to very brief and clinically insignificant episodes. In the NICU setting, an average time of eight to 12 sec with intermediate sensitivity may be adequate.
SPO 2 TARGETS
A narrow SpO 2 target of 85-89% should not be used clinically, as it may be associated with increased mortality. However, the COT trial findings do not support recommendations that targeting SpO 2 in the upper 80% range should be avoided. At the high end, there is no evidence that an SpO 2 target of 91-95% or 90-95% should be universally used in clinical practice. There are several reasons why an SpO 2 target of 91-95% is of concern. Firstly, it is a challenge to maintain infants in a tight or narrow SpO 2 target range (10, 11, 24, 25, 29, 30) , which is associated with more fluctuations in SpO 2 and periods of hypoxia and hyperoxia, with more time spent in hyperoxia. Moreover, this range will trigger more alarms, and it is likely that SpO 2 of more than 94% will occur more frequently if the low alarm is set at 89% and oxygen is increased when the alarm sounds. Secondly, this higher target was associated with significantly higher rates of severe ROP in two of the RCTs. These combined factors could lead to a resurgence of ROP. It could therefore be risky to develop guidelines that recommend SpO 2 targeting of 90-95% in clinical practice. In contrast, wider intermediate targets may allow for easier care and better compliance, and they have been associated with a decreased rate of severe ROP, without an increased morbidity or mortality (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) .
In many clinical centres, there is no accurate recording and analysis of SpO 2 and significant under recognition of alarms. Nursing notes only account for 25-30% of true desaturation episodes (46) , and neonatal medical notes reflect even less, at around 7%. Even if this is far from accurate, there are almost no recordings of higher than expected or intended SpO 2 in many NICUs around the world. It is therefore much more accurate to use normograms with SET monitors (24, 25) .
In clinical practice, adherence to planned SpO 2 targets varies between shifts and centres, mainly due to the SpO 2 targets chosen, differences in education, staff commitment to this issue, workload and accuracy and precision of monitors used. In addition, the education programmes in most nursing and medical schools emphasise the problems of hypoxia and the need to correct it, much more than the complications of hyperoxia. This means that actual versus intended SpO 2 levels are very variable (18, 24, 25, 29, 30) . When the SpO 2 target is at the higher range, SpO 2 values occur much more frequently above than below target. One study of random observations, after clinical practice was changed to aiming for SpO 2 in the 88-93% range, showed that the target was achieved 72% of the time; SpO 2 was <85% 10% of the time and, it was 96-100% 18% of the time (18) . Another study reported on 58 000 h recorded on 153 infants, with a target SpO 2 of 85-89%. The actual SpO 2 was 85-95% for 65% of the time, more than 95% for 14% of the time and <85% for 21% of the time. When the target SpO 2 was 91-95%, it was actually 85-95% for 54% of the time, more than 95% for 36% of the time and <85% for only 10% of the time (47) . It is well known by clinicians that some infants breathing oxygen have more oscillation in SpO 2 than others, and it is impossible to maintain the SpO 2 within a narrow target like 90-93% for a prolonged period of time in most of them, even when the nurse to patient ratio is one-to-one, which very rarely happens in NICUs. Therefore, a narrow high target is difficult to achieve and can lead to increased tolerance of an SpO 2 level of more than 95%. To improve the achievement of planned targets, it is necessary to use wider targets and ensure that the whole care team functions with the same goals. In this way, measures can be taken when defined targets are not respected or ignored and when an individual baby is off target and the primary nurse is carrying out other important chores. All these measures are just as important during transport and any surgical or other procedures, to try to prevent hyperoxia and hypoxia (48) . Finally, in addition to teamwork among all neonatal healthcare providers, including parents in the objective of avoiding hyperoxia may improve safety.
Finally, there are other important measures that will prevent hyperoxia. Pre-oxygenation is a dangerous and ineffective practice that should be eradicated in newborns of any gestational age, and the justification for this has been summarised elsewhere (48) . Hyperoxia should not be induced in any neonate during and after endotracheal tube suction or invasive procedures, including surgery, and it should not be allowed in the periods after extubation. Lastly, practices that can lead to severe and prolonged hyperoxaemia, like nitrogen washout without any proven benefit in important outcomes and the hyperoxic challenge test, should also be eliminated from clinical practice.
RECOMMENDATIONS FOR CARE PROVIDERS REGARDING SPO 2 RANGES, ALARM LIMITS AND VARYING AVERAGING TIME
Based on all the available evidence, the most prudent approach would be not to tolerate possible hypoxia and not to accept SpO 2 values associated with potential hyperoxia in infants breathing supplemental oxygen. Some would like to keep a preterm baby at a steady SpO 2 of 91-92% most of the time, but we learnt a long time ago that things don't work out like that way in clinical practice. It may be sensible to consider a lower SpO 2 limit of >85% and a higher limit of ≤95% when a preterm infant is breathing FiO 2 of more than 0.21 (49) . This is an intended range, which is very different to saying that an SpO 2 of 85% or 95% is normal. Rather than using narrower intended targets, like 85-89%, 90-93% or 91-95%, it may be safer to use wider intermediate SpO 2 targets such as 86-93%, 87-94%, 88-94% or something similar. However, these intermediate target ranges may be not very different from one another, due to the inherent bias of SpO 2 monitoring and the significant difference between monitors we described briefly above. The reason why we mention several ranges is that they are, or were, used in different clinical centres in the real world. For clinical practice, with the current state of knowledge, we would recommend using intention to treat or SpO 2 target of 87-94% with a monitor as the one used in the RCTs.
The averaging time for clinical care varies with monitors, and in many of them, this cannot be changed. There is always a trade-off when choosing a shorter or longer averaging time, if the monitor allows for that. The Masimo SET, which is the monitor used in all the NICU RCTs discussed in this review, needs to be set at eight to 12 sec and definitely at no more than 20 sec, to avoid seeing very brief episodes that are probably meaningless in routine care and at the same time ensure that situations that could require a clinical response are seen quickly. However, in the delivery room or during acute resuscitation, using a 2-sec averaging time could be a better option for rapidly identifying clinical situations and treatment responses. The sensitivity also varies. Most of the time, it should be on default, but high sensitivity is better in the delivery room or during resuscitations.
For infants breathing supplemental oxygen, we suggest setting the low alarm at 1% below the lower SpO 2 chosen in the clinically intended range, but never <85%, and the high alarm at 1% above the higher SpO 2 chosen, but never more than 95%. For example, if the intended range is 87-94%, the alarms would be set at 86% and 95%. Finally, the delay time should not be longer than 20 sec, to ensure that significant events are not missed.
BRIEF COMMENTS ON THE RCTS
We are all proud of scientific research successes, but sometimes the findings are just too good to be true (50) . It is not disputed that RCTs are the gold standard, but just like gold, there are RCTs of different carats and many RCTs are <50% pure. These latter studies cannot be considered as unshakable evidence.
In 2005, Dr Ioannidis started releasing papers that challenged the foundations of medical research (15, 27, (50) (51) (52) (53) , stating that 'A pervasive theme of ancient Greek literature is that you need to pursue the truth, no matter what the truth might be'. His studies have shown that many published research findings are false or completely wrong, and he has pointed out that 'The probability that a research claim is true depends on many factors, and for many current scientific fields, claimed research findings may often be simply accurate measures of the prevailing bias'. For example, Ioannidis states that a research finding is less likely to be true when more teams are involved in a scientific field and are chasing statistical significance. If time is of the essence, and to beat the competition, each team may prioritise and disseminate its most impressive 'positive' results. In addition, randomised trials that are stopped early, after fewer than 500 events, may result in large overestimations of the treatment effect (54, 55) . In the BOOST II trial, for example, there were 153 such events. There also maybe a problem with meta-analyses of trials that were stopped early (56) . The use of an interim analysis, employed by some RCTs, carries a statistical risk that, by chance, the observed effect might not represent the true effect. This may further distort the picture and may indeed lead to even smaller probabilities of the research findings being true, as proven by Ioannidis in his published articles. Ioannidis also sustains that there is an intellectual conflict of interest that pressures researchers to present the findings that are most likely to secure funding or give them more prestige. Of significant concern is his statement that much of what biomedical researchers conclude in published studies is misleading and that researchers are frequently chasing findings that will advance their careers, rather than good science. He has also stated that 'Even highly regarded researchers at prestigious institutions sometimes churn out attention-grabbing findings rather than findings likely to be right'. Ioannidis has also commented on the use of the peerreview process to suppress opposing views, and sadly, this is a well-known issue in the real world.
In addition to all of the above, it has been identified that good care should not be based solely on the findings of RCTs (15, (26) (27) (28) (50) (51) (52) (53) (57) (58) (59) . Acknowledging that evidence may still be misinterpreted or distorted by recalcitrant proponents of entrenched practices and other biases, the authors state that rational, quantitative evidence may not necessarily be the only, or even the main, factor driving healthcare decisions. Besides, many papers report significant results, and only a few published papers report neutral results, negative results or adverse events. It has been estimated that about 90% of papers report positive results and that this increases down the hierarchy of the sciences (59) . If one searches for a low p value, one can always find significant results. Results of medical research should not be reported as significant or nonsignificant, but they should be interpreted in the context of the type of study and other available evidence. Bias or confounding factors should always be considered for findings with low p values. To stop medical research being discredited by chance findings, we need more studies that avoid all the wellknown errors that can increase the chance of a significant low p value but do not really reflect what happens in the real world. (28) . Also, repeated testing and interim analysis may result in overestimations of the treatment effect. This may lead to a small probability of some of the research findings actually being true. Of course, we are not addressing at all the issues of scientific ethics and fraud, which are completely different matters and of great concern to science and psychology (60) .
The correctable weaknesses that still persist in the design, conduct, and analysis of biomedical and public health research studies, produce misleading results and waste valuable resources. Statistical precision is often used in a misleading way, and the arbitrary choice of analyses might affect the reported findings (15, 26, 27, 57) . Unfortunately, consensus building groups and bedside care providers remember the novel findings of some studies, despite significant flaws, when taking care of patients.
Putting all these matters aside, one of the most confusing aspects of the data presented by the SUPPORT and BOOST II trials is that there was no real clinical rationale provided to explain why mortality was higher in the 85-89% saturation groups. Other than flaws in design and analysis, which can occur in RCTs according to Ioannidis and others, the evidence from those trials suggests that the increased deaths were not caused by tissue hypoxia. For example, all the infants who died were reported in the BOOST II appendix, in Tables S 3.1, with the original oximeters, and S 3.2, with the revised oximeters. The vast majority died due to severe respiratory distress syndrome, severe bronchopulmonary dysplasia, grade 3-4 intraventricular haemorrhage, septicaemia and 'other' causes. We can identify absolutely no differences in those tables between the low and highSpO 2 groups or between the original and revised oximeters. We, and many others, are uncertain about why the association of SpO 2 85-89% with increased mortality occurred in two of the trials and not in the COT trial. In the current neonatal era, there are often multiple factors associated with neonatal deaths in the NICU, and we can only speculate that this discrepancy was due to one or more of those or to chance. We can only wonder what would have happened if, by chance, the 91-95% SpO 2 group had been associated with increased mortality. We are hopeful that some of these considerations are helpful to the reader and to NICU care providers.
SUMMARY OF FINDINGS
The best oxygen profiles to reduce ROP hazards, while enhancing preterm infant health and development, are still unknown. While respectfully acknowledging the existence of uncertainty, we feel that any practice guidelines or recommendations on any topic should be developed avoiding extremes and biases that could potentially have ill effects on many newborn infants. This paper provides the arguments that are needed to avoid such extremes and biases during SpO 2 monitoring. We hope that our contribution will stimulate further debate on the subject and reduce the current clinical confusion, so that doctors, nurses and respiratory therapists providing bedside care for babies make better choices that avoid both hypoxaemia and hyperoxaemia in daily practice. Rational, quantitative evidence may not necessarily be the only, or even the main, factor driving healthcare decisions.
Over the past year, many clinicians, mostly in the United States, have expressed concerns about legal action if they allow babies to have 'low' SpO 2 values in the mid-to high 80s. It has been said that it is good to practise clinical medicine based on the best interpretation of the available evidence and not to practise in a defensive manner. No one should ever practise out of fear of the legal system, and we are certain that this also includes SpO 2 targeting in very preterm infants. If a very preterm infant that had SpO 2 readings of 86 or 87% at times was to die, this could not be considered the cause of the infant's death. Furthermore, there is absolutely no evidence to prove that choosing an SpO 2 in the mid-to high 80s as the low limit is associated with, or causes, mortality. Of course, this is different to implementing an intention to treat today with a low SpO 2 limit of 85% and a high one of 89%, as these limits have been associated with a moderate increase in mortality in two RCTs. Similarly, if a very preterm newborn infant develops severe ROP, having had SpO 2 readings of 95% or 97% at times, this could not be identified as the cause of ROP. Again, this is not the same as choosing an intention to treat with an SpO 2 target of 91-95%, which has been associated with a significant increase in ROP in two RCTs. Saturations within the range of 85-95% largely exclude hyperoxia in preterm infants <29 weeks (61) .
We need to acknowledge the potential weaknesses of the RCTs summarised in this paper, which include the fact that repeated testing and interim analysis may result in overestimations of the treatment effect and lead to a small probability of some of the research findings being indeed true. We also need to recognise, and admit to, the real and persisting need for further improvements in what is currently known and used in neonatal care for neonatal oxygenation and for this complex issue of SpO 2 monitoring and targeting. For example, our clinical understanding of oxygenation status needs to be improved, and hopefully, this will happen in the not too distant future, with noninvasive monitors that can accurately measure regional tissue oxygenation, oxygen content, oxygen delivery and tissue oxygen needs. Improvements in SpO 2 targeting and monitoring require better education and understanding by bedside care providers of the issues at stake and the differences in available monitors. In addition, temporal quantification of oxygen saturation ranges and better documentation of alarms are essential (24, 25, (44) (45) (46) . Furthermore, improving oxygen saturation targeting by automated methods in preterm infants receiving invasive and non-invasive ventilation, by continuous positive airway pressure or nasal cannula, will improve the efforts to reduce hyperoxia in the NICU.
Our view is that if a centre has never used an SpO 2 target range of 85-89% before, it should not use it now and that if it has, then it should give serious consideration to modifying that practice. The same consideration should be given to an intention to treat with a target of 91-95% to avoid dangerous hyperoxaemia, a resurgence of ROP, altered brain development and other morbidities associated with hyperoxaemia.
Based on current knowledge, we must aim to avoid both hypoxaemia and hyperoxaemia in daily clinical practice. With regard to hyperoxaemia, pure oxygen should not be given if the baby's colour does not look good or seems to be cyanotic; instead, oxygenation should be assessed using an SpO 2 monitor. Using skin colour to detect hyperoxia is of little or no use, as several studies have shown that it has wide interobserver variability and a low correlation with SpO 2 (62) (63) (64) (65) (66) . A recent meta-analysis and review, that included 11 diagnostic studies with 5787 patients, showed that neither single nor combined symptoms and signs satisfactorily predicted hypoxaemia in young children (62) . Other previous studies showed that pulse oximetry is the best indicator of hypoxaemia in children (63, 64) , and this has been corroborated by large clinical studies on screening for critical congenital heart disease (65, 66) . However, improved access to pulse oximetry is still needed in many delivery rooms in the developed world and in many delivery rooms and neonatal units in developing countries. If SpO 2 does not show hypoxaemia, then oxygen should not be administered. If it does show hypoxaemia, then FiO 2 should be used at a dose that corrects the hypoxaemia, while avoiding hyperoxaemia. To achieve this in small preterm infants, it is safer to widen the target, using SpO 2 targets like 86-93%, 87-94% or 88-94% or similar. It is imperative to control the low limit but also to increase compliance with the upper limit and avoid a flip-flop phenomenon that leads to acute and significant changes and fluctuations in SpO 2 . Hopefully, this will improve with the advent of automated control of oxygenation (30, 67) .
